Aprotinin News and Research

RSS
Aprotinin, also known as bovine pancreatic trypsin inhibitor, BPTI (Trasylol, Bayer) is a protein, that is used as medication administered by injection to reduce bleeding during complex surgery, such as heart and liver surgery. Its main effect is the slowing down of fibrinolysis, the process that leads to the breakdown of blood clots. The aim in its use is to decrease the need for blood transfusions during surgery, as well as end-organ damage due to hypotension (low blood pressure) as a result of marked blood loss. The drug was temporarily withdrawn worldwide in 2007 after studies suggested that its use increased the risk of complications or death.
Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Study documents reversal of established medical practices in last decade

Study documents reversal of established medical practices in last decade

Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review

Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review

Bristol-Myers Squibb, Pfizer receive FDA approval for ELIQUIS to reduce risk of stroke and SE

Bristol-Myers Squibb, Pfizer receive FDA approval for ELIQUIS to reduce risk of stroke and SE

FDA approves Baxter's TISSEEL for general hemostasis in surgery

FDA approves Baxter's TISSEEL for general hemostasis in surgery

Baxter's ARTISS phase III study results in face lift surgery presented at AAPS meeting

Baxter's ARTISS phase III study results in face lift surgery presented at AAPS meeting

USPTO grants second patent to Angiochem's EPiC drugs

USPTO grants second patent to Angiochem's EPiC drugs

Pediatric physicians present 12 research abstracts, posters at Cardiology 2011

Pediatric physicians present 12 research abstracts, posters at Cardiology 2011

Omeros receives exclusive license for new series of antifibrinolytic agents

Omeros receives exclusive license for new series of antifibrinolytic agents

Sinobiopharma receives certificate for using Gabexate Mesylate as pharmaceutical raw material

Sinobiopharma receives certificate for using Gabexate Mesylate as pharmaceutical raw material

Qrxpharma forms an alliance with Liaoning Nuokang Medicines to commercialise its venomics assets

Qrxpharma forms an alliance with Liaoning Nuokang Medicines to commercialise its venomics assets

Risk of death may be higher with aprotinin commonly used during cardiac surgery

Risk of death may be higher with aprotinin commonly used during cardiac surgery

New medical adhesive

New medical adhesive

A new finding in liver transplantation and antifibrinolytics?

A new finding in liver transplantation and antifibrinolytics?

Study confirms aprotinin drug increases cardiac surgery death rate

Study confirms aprotinin drug increases cardiac surgery death rate

FDA issues communication on ongoing safety review of Aprotinin injection

FDA issues communication on ongoing safety review of Aprotinin injection

Anti-fibrinolytics reduce blood loss during cardiac surgery

Anti-fibrinolytics reduce blood loss during cardiac surgery

FDA committees recommend continued U.S. marketing for Trasylol

FDA committees recommend continued U.S. marketing for Trasylol

Study questions risks of aprotinin during heart surgery

Study questions risks of aprotinin during heart surgery

Proper use of aprotinin to reduce bleeding during heart surgery does not increase the risk of heart attack or stroke

Proper use of aprotinin to reduce bleeding during heart surgery does not increase the risk of heart attack or stroke